Neurogene Inc. Stock Split Ratio
Neurogene Inc. (NGNE) had Stock Split Ratio of 25.00% as of 2023-12-18, per its 10-K filed 2025-03-24.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2025-03-24
- Neurogene Inc. stockholders' equity note, stock split, conversion ratio for the quarter ending 2014-03-31 was 5.21%.
- Neurogene Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2014 was 5.21%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 3 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 9 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|---|---|---|---|
| 2023-12-18 | 25.00% 10-K · filed 2025-03-24 | |||||
| 2023-09-25 | 20.00% 10-Q · filed 2023-11-14 | |||||
| 2014-12-31 | 5.21% 10-K · filed 2015-03-16 | |||||
| 2014-09-30 | 5.21% 10-Q · filed 2014-11-04 | |||||
| 2014-06-30 | 5.21% 10-Q · filed 2014-08-11 | |||||
| 2014-03-31 | 5.21% 10-Q · filed 2014-05-13 | |||||
| 2014-02-27 | 5.21% 10-K · filed 2016-03-14 | 5.21% 10-Q · filed 2014-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |